The Indonesian government secured 100 million doses of vaccines powder from AstraZenecca (LSE: AZN), a pharmaceutical firm listed on the London Stock Exchange - Photo by SOEs Ministry Office

JAKARTA (TheInsiderStories) – The Indonesian government secured 100 million doses of vaccines powder from AstraZenecca (LSE: AZN), a pharmaceutical firm listed on the London Stock Exchange, said the ministers on Wednesday (10/15). It hopes that the vaccine will come gradually starting the first semester of 2021.

“We had a meeting with AstraZeneca and it went well. Indonesia submitted a request for 100 million doses of vaccine for 2021 and AstraZeneca welcomed the request,” said foreign minister, Retno Marsudi, in a virtual conference, yesterday.

Beside signed the deal, she and state own enterprises minister, Erick Thohir, also met with the CEO of Coalition for Epidemic Preparedness Innovations(CEPI) to explore the strategic cooperation. She revealed, CEPI was hold a due diligence on state-owned drug-maker, PT Bio Farma to develop vaccine manufacturing.

The ministers will also hold a meetings and discussions with the Director General of World Health Organization, Global Alliance for Vaccines and Immunization, Coalition for Epidemic Preparedness Innovations within the framework of the COVAC facility. The trips part of Joko Widodo’ ministers effort to run a vaccine test this November

Last week, coordinating minister for maritime and investment affairs, Luhut Binsar Pandjaitan, together with minister of health, Terawan Agus Putranto, and CEO of drug-maker, Bio Farma, Honesti Basyir, has met Cansino, Sinopharm, and Sinovac. Putranto said the government will carry out simulations in several health centers.

Since the end of September, training has also been carried out for health workers on the procedures for the vaccination. As known, vaccines from the three companies have entered the final stage of clinical trial phase 3 and are in the process of obtaining Emergency Use Authorization in a number of countries. Cansino is conducting phase 3 clinical trials in China, Saudi Arabia, Russia and Pakistan.

Then, Sinopharm conducted Phase 3 clinical trials in China, United Arab Emirates (UAE), Peru, Morocco and Argentina. While, Sinovac is conducting clinical trials in phase 3 in China, Indonesia, Brazil, Turkey, Bangladesh, and Chile.

The three companies obtained Emergency Use Authorization from the Chinese Government in July 2020. The UAE Government also provided emergency use authorization to G42 produced by Sinopharm. The number of vaccines covered by each company varies, depending on production capacity and commitments to other buyers.

For this year, Cansino has undertaken 100,000 vaccines (single dose) in November 2020 and around 20 million for 2021. Sinopharm undertakes 15 million doses of vaccine (dual dose) in this year, of which 5 million doses will begin coming next month.

While, Sinovac has committed 3 million doses of vaccine by the end of December, with a commitment to deliver 1.5 million doses of vaccine (single dose vials) in the first week of November, another 1.5 million doses of vaccine (single dose vials) in the first week of December 2020, plus 15 million doses of vaccine in bulk form. For 2021, Sinopharm seeks 50 million (dual dose), Cansino 20 million (single dose), Sinovac 125 million (dual dose).

“China is willing to cooperate with Indonesia in vaccine research, production and distribution, as well as support exchanges between related medical research institutions to help ensure access to affordable vaccines throughout the region and around the world,” said Chinese foreign minister, Wang Yi, after the meeting.

While, today, Marsudi said in a virtual presser, she and Thohir will also have a diplomatic meetings with the British foreign minister, Swiss’ Vice President, and meet several companies from Switzerland.

Bio Farma is a state-owned pharmaceutical holding company that is responsible for the COVID-19 vaccine, together with its three subsidiaries, namely PT Kimia Farma Tbk (IDX: KAEF), PT Indofarma Tbk (IDX: INAF), and PT Phapros Tbk (IDX: PEHA).

Written by Editorial Staff, Email: